| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab170522-100μg |
100μg |
现货  |
| |
| Ab170522-1mg |
1mg |
现货 |
| |
| Ab170522-5mg |
5mg |
现货 |
| |
| Ab170522-10mg |
10mg |
期货 |
|
| 产品名称 | Otelixizumab (anti-CD3), CD3e 抗体 |
|---|---|
| 别名 | 奥昔组单抗 | 奥替利珠单抗(抗 CD3) |
| 英文别名 | Anti-CD3 Reference Antibody (otelixizumab) | Otelixizumab | ChAglyCD3 | TRX 4 | 4930549J05Rik antibody | A430104F18Rik antibody | AW552088 antibody | Cd247 antibody | CD247 antigen antibody | CD247 antigen, zeta subunit antibody | CD247 molecule antibody |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CD3D |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 结合剂 |
| 作用机制 | CD3e 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | lambdaC2 |
| SDS-PAGE | 27.0 kDa (Light Chain) & 51.5 kDa (Heavy Chain), under reducing conditions; 181.4 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 881191-44-2 |
| 分子类型 | 抗体 |
Otelixizumab (anti-CD3) (Ab170522) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD3 with Otelixizumab (anti-CD3) (Ab170522) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156150).
Otelixizumab (anti-CD3) (Ab170522) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD3 (red) with Otelixizumab (anti-CD3) (Ab170522) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Otelixizumab (anti-CD3) (Ab170522) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD3 (red) with Otelixizumab (anti-CD3) (Ab170522). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Otelixizumab (anti-CD3) (Ab170522) - SEC
The purity of Otelixizumab (anti-CD3) (Ab170522) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F1012830 |
分析证书 | 24-10-24 | Ab170522 |
| ZJ24F1012829 |
分析证书 | 24-10-24 | Ab170522 |
| ZJ24F1012828 |
分析证书 | 24-10-24 | Ab170522 |
| ZJ23F1001497 |
分析证书 | 23-11-02 | Ab170522 |
¥379.90
| 1. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S et al.. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.. N Engl J Med, 352 (25): (2598-608). [PMID:15972866] |
| 2. Chatenoud L, Bluestone JA. (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity.. Nat Rev Immunol, 7 (8): (622-32). [PMID:17641665] |
| 3. Kaufman A, Herold KC. (2009) Anti-CD3 mAbs for treatment of type 1 diabetes.. Diabetes Metab Res Rev, 25 (4): (302-6). [PMID:19319985] |
| 4. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry Jr RJ, Bode B, Aronoff S, Holland C, Carlin D et al.. (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.. Lancet, 378 (9790): (487-97). [PMID:21719095] |
| 5. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.. Eur J Immunol, 23 (2): (403-11). [PMID:8436176] |
| 6. de Saint Basile G, Geissmann F, Flori E, Uring-Lambert B, Soudais C, Cavazzana-Calvo M, Durandy A, Jabado N, Fischer A, Le Deist F. (2004) Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3.. J Clin Invest, 114 (10): (1512-7). [PMID:15546002] |
| 7. Phillips, J H JH and 5 more authors.. (1992) Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins.. The Journal of experimental medicine, (1): [PMID:1372642] |
| 8. Barber, E K EK, Dasgupta, J D JD, Schlossman, S F SF, Trevillyan, J M JM and Rudd, C E CE.. (1989) The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2470098] |
| 9. Alexander, D D and 5 more authors.. (1989) Dephosphorylation of the human T lymphocyte CD3 antigen.. European journal of biochemistry, (15): [PMID:2540970] |
| 10. van den Elsen, P P, Georgopoulos, K K, Shepley, B A BA, Orkin, S S and Terhorst, C C.. (1986) Exon/intron organization of the genes coding for the delta chains of the human and murine T-cell receptor/T3 complex.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2939461] |
| 11. Tunnacliffe, A A, Sims, J E JE and Rabbitts, T H TH.. (1986) T3 delta pre-mRNA is transcribed from a non-TATA promoter and is alternatively spliced in human T cells.. The EMBO journal, [PMID:3488209] |
| 12. van den Elsen, P P and 6 more authors.. (1984) Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex.. Nature, [PMID:6095101] |
| 13. Wilde, M I MI and Goa, K L KL.. (1996) Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.. Drugs, [PMID:8861551] |
| 14. Doucey, Marie-Agnès MA and 7 more authors.. (2003) CD3 delta establishes a functional link between the T cell receptor and CD8.. The Journal of biological chemistry, (31): [PMID:12215456] |
| 15. Salomon, Arthur R AR and 10 more authors.. (2003) Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.. Proceedings of the National Academy of Sciences of the United States of America, (21): [PMID:12522270] |
| 16. Dadi, Harjit K HK, Simon, Amos J AJ and Roifman, Chaim M CM.. (2003) Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency.. The New England journal of medicine, (6): [PMID:14602880] |
| 17. Jin, Pei P and 7 more authors.. (2004) PCR isolation and cloning of novel splice variant mRNAs from known drug target genes.. Genomics, [PMID:15028279] |
| 18. Brill, Laurence M LM and 5 more authors.. (2004) Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.. Analytical chemistry, (15): [PMID:15144186] |
| 19. Arnett, Kelly L KL, Harrison, Stephen C SC and Wiley, Don C DC.. (2004) Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment.. Proceedings of the National Academy of Sciences of the United States of America, (16): [PMID:15534202] |
| 20. Yu, Grace P and 13 more authors.. (2011) Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID.. Pediatric transplantation, [PMID:21883749] |
| 21. Zugmaier, Gerhard G, Klinger, Matthias M, Schmidt, Margit M and Subklewe, Marion M.. (2015) Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.. Molecular immunology, [PMID:25883042] |
首页
400-620-6333
